Iron overload in myelodysplastic syndromes

Harvey, R. Donald; Fausel, Christopher A.
April 2010
American Journal of Health-System Pharmacy;4/1/2010 Supplement, Vol. 67, pS2
Academic Journal
The article focuses on iron overload, a clinical complication resulted from myelodysplastic syndromes (MDS). It discusses the importance of management strategies in patients with MDS to address the consequences of overload, and the use of iron chelation therapy (ICT) as a treatment for MDS. It says that the balance between clinical outcomes, toxicity caused by iron overload and economic burden should be carefully considered when making plans for the management of patients with MDS.


Related Articles

  • Myelodysplastic syndromes and the role of iron overload. Harvey, R. Donald // American Journal of Health-System Pharmacy;4/1/2010 Supplement, Vol. 67, pS3 

    Purpose. The epidemiology of myelodysplastic syndromes (MDS) and iron overload, recent clinical findings that highlight the importance of actively managing iron overload, and recommendations for initiating and maintaining iron chelation therapy (ICT) are summarized. Summary. MDS are a variety of...

  • Iron chelation therapy in myelodysplastic syndromes. Fausel, Christopher A. // American Journal of Health-System Pharmacy;4/1/2010 Supplement, Vol. 67, pS10 

    Purpose. To understand how to appropriately recognize and manage iron overload with iron chelation therapy (ICT) in patients with myelodysplastic syndromes (MDS), evaluation of the role of different agents available for management of iron overload, including efficacy, safety, and...

  • The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes. Petrou, Emmanouil; Mavrogeni, Sophie; Karali, Vasiliki; Kolovou, Genovefa; Kyrtsonis, Marie-Christine; Sfikakis, Petros P.; Panayiotidis, Panayiotis // Revista Brasileira de Hematologia e Hemoterapia;Jul/Aug2015, Vol. 37 Issue 4, p252 

    Myelodysplastic syndromes represent a group of heterogeneous hematopoietic neoplasms derived from an abnormal multipotent progenitor cell, characterized by a hyperproliferative bone marrow, dysplasia of the cellular hemopoietic elements and ineffective erythropoiesis. Anemia is a common finding...

  • Iron Chelation Therapy in Myelodysplastic Syndromes. Messa, Emanuela; Cilloni, Daniela; Saglio, Giuseppe // Advances in Hematology;2010, Vol. 2010, p1 

    Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload. Iron chelation therapy may be a therapeutic...

  • Iron-Overload�Related Disease in HFE Hereditary Hemochromatosis. Allen, Katrina J.; Gurrin, Lyle C.; Constantine, Clare C.; Osborne, Nicholas J.; Delatycki, Martin B.; Nicoll, Amanda J.; McLaren, Christine E.; Bahlo, Melanie; Nisselle, Amy E.; Vulpe, Chris D.; Anderson, Gregory J.; Southey, Melissa C.; Giles, Graham G.; English, Dallas R.; Hopper, John L.; Olynyk, John K.; Powell, Lawrie W.; Gertig, Dorota M. // New England Journal of Medicine;1/17/2008, Vol. 358 Issue 3, p221 

    Background: Most persons who are homozygous for C282Y, the HFE allele most commonly asssociated with hereditary hemochromatosis, have elevated levels of serum ferritin and transferrin saturation. Diseases related to iron overload develop in some C282Y homozygotes, but the extent of the risk is...

  • Talasemi Major'lu Hastalarda QT Dispersiyonu ve Kalp Hızı DeÄŸiÅŸkenliÄŸinin Ferritin ile Ä°liÅŸkisi: Yüksek Ferritin Kalp Demir Yükünden Çok Sempatovagal Disregulasyonu mu Gösteriyor? ÇEKİÇ, Şükrü; KARAKAŞ, Zeynep; YALIN, Kivanç; BİLGE, Ahmet Kaya; EKER ÖMEROĞLU, Rukiye // Journal of the Child / Cocuk Dergisi;Sep2013, Vol. 12 Issue 3, p125 

    Introduction: The most important cause of the morbidity and llie mortality in patients with thalassemia major is iron overload. Cardiac complications due to the iron overload are the primary causes of mortality in these patients. Increased QT dispersion and decreased heart variability are known...

  • Reconsidering the Management of Younger Patients with Myelodysplastic Syndrome. Bourret, Jeffrey A. // American Health & Drug Benefits;Nov/Dec2012, Vol. 5 Issue 7, p465 

    In this article the author discusses the management of myelodysplastic syndrome in younger patients and the article "Hematologic Complications, Healthcare Utilization, and Costs in Commercially Insured Patients with Myelodysplastic Syndrome Receiving Supportive Care" by Annette Powers et al. He...

  • Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up. IMPROTA, SALVATORE; VILLA, MARIA ROSARIA; VOLPE, ANTONIO; LOMBARDI, ANGELA; STIUSO, PAOLA; CANTORE, NICOLA; MASTRULLO, LUCIA // Oncology Letters;2013, Vol. 6 Issue 6, p1774 

    Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis that results in peripheral cytopenias. Anemia is the most common symptom of MDS and the majority of patients become transfusion-dependent with the risk of iron overload, which may lead to cardiac, hepatic and...

  • Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndrome. Lin, Che-Hung; Yeh, Su-Peng; Lin, Tze-Yi // Annals of Hematology;Nov2015, Vol. 94 Issue 11, p1925 

    The article presents case study of a 62-year-old man with pancytopenia. Bone marrow study of the patient confirmed myelodysplastic syndrome, and the patient treated with azacitidine. After the second cycle of the azacitidine recurrent fever developed followed by the presence of erythematous...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics